Small molecule · Inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) · developed by Prelude Therapeutics
PRT3645 is an orally bioavailable, brain-penetrant small molecule that selectively inhibits the kinases CDK4 and CDK6. By blocking Rb phosphorylation in early G1, it arrests the cell cycle and reduces tumor cell proliferation. It is being studied in breast cancer, glioblastoma, head and neck squamous cell carcinoma, malignant mesothelioma, non-small cell lung cancer, sarcoma and endometrial cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05538572 | Phase 1 | Breast Cancer | Completed | PRLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerEndometrial CancerGlioblastomaHead and Neck Squamous Cell CarcinomaMalignant MesotheliomaNon-small Cell Lung CancersSarcoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.
See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRLD catalysts and pipeline →